Our professionals

Dr. Bruno Paiva

Director of the Flow Cytometry Platform.
Co-Director of the Hemato-Oncology Program.
Preferential dedication to multidimensional flow cytometry analysis of hematological malignancies.

Be part of: Cima Universidad de Navarra

Professional career

Graduated in Pharmacy in 2007 from the University of Coimbra, Portugal.

Master in Cancer Biology in 2009 at the University Hospital of Salamanca. University of Salamanca. Cancer Research Centre.

Doctor of Medicine in 2011 by the University of Salamanca.


He has been PI or Co-PI in 12 R&D projects funded through competitive calls from public or private entities, and has established more than 15 R&D collaboration agreements with companies such as Amgen, Becton Dickinson, BMS-Celgene, Miltenyi, Janssen, Roche, Sanofi and Takeda.

His research laboratory has been at the core of more than 20 national and international clinical trials in multiple myeloma and acute myeloid leukemia.


His research objectives are intrinsically related to the dual nature of his clinical and research laboratory: to provide state-of-the-art biomarkers for laboratory diagnostics through intensive basic and translational research.

He prioritizes its research in monoclonal gammopathies such as multiple myeloma (MM), light chain amyloidosis (AL) or Waldenstöm's macroglobulinemia (WM), and such research can be classified into five well-defined areas:

  1. Pathogenesis of MM, AL and WM.
  2. Risk of transformation in non-IgM and IgM MGUS
  3. Circulating tumor cells (CTCs)
  4. Minimal residual disease (MRD)
  5. Immune monitoring

His laboratory is now escalating our translational research program into other hematological malignancies such as acute myeloid leukemia.


As an educator

Visiting Professor in the Master of Biomedical Research and Biomedical Engineering at the Universidad de Navarra.

Organizer of numerous practical courses on immunophenotyping by flow cytometry.

As a researcher

With 13 years of research career, he is author in 150 publications, being first author in 37, last author and/or corresponding author in 15. Among them, there are several publications in the best journals such as N Engl J Med (n = 1), Nat Med (n = 1), Cancer Cell (n = 2), Lancet Oncol (n = 4) and J Clin Oncol (n = 4), and a high number of publications in the two most important journals of Hematology: Blood (n = 26) and Leukemia (n = 23). More than 90% of the publications are in Q1 of their respective specialty.

His publications have more than 5,200 citations (without self-citations) and an average of 51 citations per publication.

Frequent invited speaker at the most relevant international congresses in the field of Hematology and Flow Cytometry (~20/year).

Imagen de un icono azul con un documento certificado.


I have been awarded with numerous recognitions, including the Bart Barlogie Young Investigator Award for outstanding research developed in multiple myeloma, and The Future Leaders in Hematology Award of the 2015 Celgene Awards for Clinical Research in Haematology.